<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="EN" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="pmc-domain-id">82</journal-id><journal-id journal-id-type="pmc-domain">aac</journal-id><journal-id journal-id-type="publisher-id">ANTIMICROB AGENTS CHEMOTHER</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology (ASM)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC89930</article-id><article-id pub-id-type="pmcid-ver">PMC89930.1</article-id><article-id pub-id-type="pmcaid">89930</article-id><article-id pub-id-type="pmcaiid">89930</article-id><article-id pub-id-type="pmid">10817726</article-id><article-id pub-id-type="doi">10.1128/aac.44.6.1667-1673.2000</article-id><article-id pub-id-type="publisher-id">0674</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Antiviral Agents</subject></subj-group></article-categories><title-group><article-title>Pharmacokinetics and Safety of AMD-3100, a Novel Antagonist of the CXCR-4 Chemokine Receptor, in Human Volunteers</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Hendrix</surname><given-names initials="CW">Craig W.</given-names></name><xref ref-type="aff" rid="N0x98a3aa8.0x96c8ba8">1</xref><xref ref-type="author-notes" rid="FN150">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Flexner</surname><given-names initials="C">Charles</given-names></name><xref ref-type="aff" rid="N0x98a3aa8.0x96c8ba8">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>MacFarland</surname><given-names initials="RT">Ronald T.</given-names></name><xref ref-type="aff" rid="N0x98a3aa8.0x96c8ba8">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Giandomenico</surname><given-names initials="C">Christen</given-names></name><xref ref-type="aff" rid="N0x98a3aa8.0x96c8ba8">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fuchs</surname><given-names initials="EJ">Edward J.</given-names></name><xref ref-type="aff" rid="N0x98a3aa8.0x96c8ba8">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Redpath</surname><given-names initials="E">Ella</given-names></name><xref ref-type="aff" rid="N0x98a3aa8.0x96c8ba8">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bridger</surname><given-names initials="G">Gary</given-names></name><xref ref-type="aff" rid="N0x98a3aa8.0x96c8ba8">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Henson</surname><given-names initials="GW">Geoffrey W.</given-names></name><xref ref-type="aff" rid="N0x98a3aa8.0x96c8ba8">2</xref></contrib></contrib-group><aff id="N0x98a3aa8.0x96c8ba8"> Division of Clinical Pharmacology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287,<sup>1</sup> and  AnorMED, Inc., Langley, British Columbia, Canada V2Y 1N5<sup>2</sup></aff><author-notes><fn id="FN150"><label>*</label><p>Corresponding author. Mailing address: Division of Clinical Pharmacology, Johns Hopkins University School of Medicine, Harvey 502, 600 N. Wolfe St., Baltimore, MD 21287. Phone: (410) 955-9707. Fax: (410) 955-9708. E-mail: <email>chendrix@jhmi.com</email>.</p></fn></author-notes><pub-date pub-type="ppub"><month>6</month><year>2000</year></pub-date><volume>44</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">2485</issue-id><fpage>1667</fpage><lpage>1673</lpage><history><date date-type="received"><day>9</day><month>8</month><year>1999</year></date><date date-type="rev-request"><day>15</day><month>1</month><year>2000</year></date><date date-type="accepted"><day>18</day><month>3</month><year>2000</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>06</month><year>2000</year></date></event><event event-type="pmc-live"><date><day>12</day><month>09</month><year>2002</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2019-10-31 10:56:17.363"><day>31</day><month>10</month><year>2019</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2000, American Society for Microbiology</copyright-statement><copyright-year>2000</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ac001667.pdf"/><abstract><p>AMD-3100, a bicyclam, is a novel agent that uniquely inhibits the entry of human immunodeficiency virus type 1 (HIV-1) into CD4<sup>+</sup> T cells via selective blockade of the chemokine CXCR-4 receptor. Twelve healthy volunteers were given AMD-3100 as a single 15-min intravenous infusion at 10, 20, 40, or 80 &#956;g/kg. Five subjects also received a single subcutaneous injection of AMD-3100 (40 or 80 &#956;g/kg). Three subjects received two escalating oral doses each (80 and 160 &#956;g/kg). All subjects tolerated their dose(s) well without any grade 2 toxicity or dose adjustment. Six subjects experienced mild, transient symptoms, primarily gastrointestinal in nature and not dose related. All subjects experienced a dose-related elevation of the white blood cell count, from 1.5 to 3.1 times the baseline, which returned to the baseline 24 h after dosing. AMD-3100 demonstrated dose proportionality for the maximum drug concentration in serum (<italic>C</italic><sub>max</sub>) and the area under the concentration-time curve from 0 h to &#8734; (AUC<sub>0&#8211;&#8734;</sub>) over the entire dose range. At the highest intravenous dose (80 &#956;g/kg), the median <italic>C</italic><sub>max</sub> was 515 (range, 470 to 521) ng/ml and the AUC<sub>0&#8211;&#8734;</sub> was 1,044 (range, 980 to 1,403) ng-h/ml. The median systemic absorption after subcutaneous dosing was 87% (range, 67 to 106%). No drug was detectable in the blood following oral dosing. Using a two-compartment model, the median pharmacokinetic parameter estimates (ranges) were as follows: volume of distribution, 0.34 (0.27 to 0.36) liter/kg; clearance, 1.30 (0.97 to 1.34) liters/h; elimination half-life, 3.6 (3.5 to 4.9) h. After a single, well-tolerated intravenous dose of AMD-3100, concentrations were sustained for 12 h above the in vitro antiretroviral 90% inhibitory concentrations and for 8 h above antiviral concentrations identified in the SCID-hu Thy/Liv mouse model of HIV infection.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>